Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2021-05-12 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
Earnings Release Classification · 99% confidence The document is titled "Inventiva reports first quarter 2021 financial information..." and details cash position, revenues for Q1 2021, and business updates. This content structure—reporting key financial metrics for a specific, non-annual period (Q1)—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since the document focuses on key highlights (cash, revenue, partnership updates) and explicitly states the financial information is non-audited (footnote 1), it aligns best with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not the comprehensive Interim Report (IR) which would typically contain full financial statements, nor is it the Annual Report (10-K). The document is a press release announcing results, not an announcement of a report's publication (RPA). Q1 2021
2021-05-12 English
Inventiva : information financière du 1er trimestre 2021 et point sur le partenariat avec AbbVie dans le domaine des maladies auto-immunes
Earnings Release Classification · 99% confidence The document is titled "Inventiva : information financière du 1er trimestre 2021" and details the company's cash position, revenue for Q1 2021, and provides an update on a partnership. It explicitly states that the financial information is unaudited ("Information financière non auditée") and focuses on a period shorter than a full year (Q1 2021). This structure—financial highlights for a quarterly period, including cash flow and revenue, but not being a full annual report (10-K) or a standalone audit report (AR)—strongly indicates an Interim/Quarterly Report. The document also mentions the next financial update date (H1 2021 results on July 28, 2021), further confirming its periodic reporting nature. It is not a short announcement of a report (RPA/RNS) as it contains substantial financial detail and operational updates. Q1 2021
2021-05-12 French
Inventiva annonce sa participation à la « 7th Annual Truist Securities Life Sciences Summit »
Report Publication Announcement Classification · 99% confidence The document is a press release from Inventiva announcing its participation in the '7th Annual Truist Securities Life Sciences Summit' where management will hold investor meetings. This type of announcement, detailing participation in investor conferences or roadshows, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about investor engagement. Since the text is an announcement about management meeting with investors at a specific conference, it strongly relates to investor relations activities. Given the options, 'Investor Presentation' (IP) is the closest fit for content related to management presenting company information to investors, even though this specific document is an announcement of attendance rather than the presentation slides themselves. However, looking closely at the definitions, this is an announcement about management meetings at a summit, which is a form of investor engagement. It is not a formal financial report (10-K, IR, ER, MRQ) or a formal voting/proxy document (AGM-R, DEF 14A). It is an announcement about investor engagement, which often falls under Investor Presentation (IP) or sometimes Regulatory Filings (RNS) if it were purely administrative. Given the context of management meeting investors to discuss the company, IP is the most appropriate category for investor-facing material announcements, although RPA (Report Publication Announcement) is also a possibility if it were announcing a different report. Since it's about investor meetings, IP is chosen.
2021-04-26 French
Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the company, Inventiva, will participate in the '7th Annual Truist Securities Life Sciences Summit' through one-on-one investor meetings on May 4-5, 2021. This type of announcement, detailing participation in an investor conference or roadshow, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or more accurately, a general announcement related to investor relations activities. Since the document is short (4125 chars) and primarily serves to inform the market about management's upcoming engagement with investors at a specific event, it aligns best with the general category of investor communication. However, none of the specific codes perfectly match 'Investor Conference Participation Announcement'. Given the options, this is not a formal regulatory filing (10-K, IR, ER), nor a specific transaction (DIV, POS, DIRS). It is an announcement intended for investors about management availability. The closest fit among the provided options that covers general investor-facing activities, especially those related to strategy and market positioning discussions (which happen at these summits), is Investor Presentation (IP), although it is an announcement *about* meetings rather than the presentation slides themselves. A stronger candidate might be Regulatory Filings (RNS) as a general announcement, but since the content is purely about investor engagement, IP is often used broadly for such communications, or it could be considered a general announcement (RNS). Given the context of engaging with investors at a summit, and the lack of a specific 'Investor Roadshow Announcement' code, I will classify it as an Investor Presentation (IP) as it relates directly to investor engagement strategy, or RNS as a general announcement. Since it is an announcement about management engaging with investors, and not a formal report, RNS (Regulatory Filings/General Announcement) is the safest fallback for an announcement that doesn't fit the specific report types. However, because the core subject is investor meetings at a life sciences summit, which is a key part of investor relations, I will lean towards IP as the intended category for investor-focused communications that aren't formal earnings or financial reports. Re-evaluating against the definitions: It is not a DEF 14A (Remuneration), not an ER (Earnings Release), not an MDA (Management Discussion). It is an announcement about management engaging with investors. This is often grouped with Investor Presentations (IP) or sometimes as a general Regulatory Filing (RNS). Given the high specificity required, and that it's an announcement about management engaging investors, I will select RNS as the most appropriate general announcement category, as it is not a formal presentation document itself.
2021-04-26 English
Nomination de Martine Zimmermann en tant qu’administratrice indépendante au Conseil d’Administration d’Inventiva
Board/Management Information Classification · 99% confidence The document is a press release dated April 19, 2021, announcing the appointment of Martine Zimmermann as an independent director to the Board of Directors of Inventiva. This type of announcement, concerning changes in the company's board of directors or senior management, directly corresponds to the definition of 'Board/Management Information'. The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the most appropriate classification is MANG.
2021-04-19 French
Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
Board/Management Information Classification · 99% confidence The document is a press release dated April 19, 2021, announcing the appointment of Martine Zimmermann to the Board of Directors. This directly relates to changes in the company's board of directors and senior management. This aligns perfectly with the definition for Board/Management Information (MANG). Although it mentions future ratification at a general meeting, the primary purpose is the announcement of the appointment itself, not the voting results (DVA) or AGM materials (AGM-R). The document length is substantial (9440 chars), indicating it is the primary announcement, not a brief RPA.
2021-04-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.